The data were better than the results reported in previous clinical trials enrolling general population of NSCLC patients.18, 19, 20 These findings revealed that patients with ROS1+NSCLC were likely to be more responsive to pemetrexed‐based chemotherapy, which were broadly in line with results of previous studies conducted in ROS1+NSCLC.8, 9, 10, 21 However, the benefit of platinum‐pemetrexed chemotherapy was less than that of crizotinib treatment. Here, ROS1 is linked to non-small cell lung carcinoma.